Onkologie. 2022:16(1):46-49 | DOI: 10.36290/xon.2022.008

Surgical treatment of a frontal bone lesion in a patient with multiple myeloma

Petr Skalický, Ondřej Bradáč
Neurochirurgická klinika 2. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Motol, Praha

Although the main modality for the treatment of multiple myeloma is systemic therapy, in some cases surgical procedures may be justified. Surgical solution may be indicated in case of bone complications (deformities, stability), but also other symptomatic lesions to ensure a better quality of life. It becomes important especially in the absence of diagnosis. When bone infiltration is suspected in any lesion of the skull, emphasis must be placed on detailed examination by imaging methods - especially by means of magnetic resonance imaging and laboratory examinations and referral of the patient to the appropriate specialized clinic.

Keywords: myelom, plazmocytom, neurochirurgie.

Published: February 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skalický P, Bradáč O. Surgical treatment of a frontal bone lesion in a patient with multiple myeloma. Onkologie. 2022;16(1):46-49. doi: 10.36290/xon.2022.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Röllig C, Knop S, Bornhäuser M. Multiple myeloma. The Lancet. 2015;385(9983):2197-2208. Go to original source... Go to PubMed...
    2. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107(3): 904-906. Go to original source... Go to PubMed...
    3. Myeloma - Cancer Stat Facts [online]. National Cancer Institute - SEER. [cit. 27-9-2021]. Dostupné z: https://seer.cancer.gov/statfacts/html/mulmy.html.
    4. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014;15(12):e538-e548. Go to original source... Go to PubMed...
    5. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 2007;356(25):2582-2590. Go to original source... Go to PubMed...
    6. Dimopoulos MA, Goldstein J, Fuller L, et al. Curability of solitary bone plasmacytoma. J. Clin. Oncol. 1992;10(4):587-590. Go to original source... Go to PubMed...
    7. Yeh Y, Chambers J, Gaugris S, et al. Indirect Comparison of the Efficacy of Melphalan-Prednisone-Bortezomib Relative to Melphalan-Prednisone-Thalidomide and Melphalan-Prednisone for the First Line Treatment of Multiple Myeloma. Blood. 2008;112(11):2367. Go to original source...
    8. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N. Engl. J. Med. 1996;335(2):91-97. Go to original source... Go to PubMed...
    9. Dimopoulos MA and Terpos E. Multiple myeloma. Ann. Oncol. 2010;21:143-150. Go to original source... Go to PubMed...
    10. Patel AJ, Adams GJ, Humphries WE, et al. Multiple myeloma presenting as solitary mass in the posterior fossa. J. Clin. Neurosci. 2010;17(11):1457-1459. Go to original source... Go to PubMed...
    11. Cerase A, Tarantino A, Gozzetti A, et al. Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. Neuroradiology. 2008;50(8):665-674. Go to original source... Go to PubMed...
    12. Kuo YH, Huang WC, Wu JC. Surgical Treatment for a Giant Solitary Plasmacytoma with Skull Erosion. Cureus. 2018. Go to original source...
    13. Singh AD, Chacko AG, Chacko G, et al. Plasma cell tumors of the skull. Surg. Neurol. 2005;64(5):434-438; discussion 438-439. Go to original source... Go to PubMed...
    14. Ma XJ, Li D, Wang L, et al. Clinical features, radiological profiles, and surgical outcomes of primary intracranial solitary plasmacytomas: a report of 17 cases and a pooled analysis of individual patient data. J. Neurooncol. 2019;142(2):263-272. Go to original source... Go to PubMed...
    15. Sahin F, Saydam G, Ertan Y, et al. Dural plasmacytoma mimicking meningioma in a patient with multiple myeloma. J. Clin. Neurosci. 2006;13(2):259-261. Go to original source... Go to PubMed...
    16. Schluterman KO, Fassas AB-T, Van Hemert RL, et al. Multiple myeloma invasion of the central nervous system. Arch. Neurol. 2004;61(9):1423-1429. Go to original source... Go to PubMed...
    17. Khan SA, Laulloo A, Vats A, et al. Microvascular decompression: incidence and prevention of postoperative CSF leakage in a consecutive series of 134 patients. Br. J. Neurosurg. 2020;34(4):416-418. Go to original source... Go to PubMed...
    18. Lee SC, Wu CT, Lee ST, et al. Cranioplasty using polymethyl methacrylate prostheses. J. Clin. Neurosci. 2009; 16(1):56-63. Go to original source... Go to PubMed...
    19. Sharavanan GM, Jayabalan S, Rajasukumaran K, et al. Cranioplasty using presurgically fabricated presterilised polymethyl methacrylate plate by a simple, cost-effective technique on patients with and without original bone flap: study on 29 patients. J. Maxillofac. Oral. Surg. 2015;14(2):378-385. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.